Gene Therapy RP-A501 Shows Promising Phase 1 Results in Danon Disease
Rocket Pharmaceuticals has announced the long-term safety and efficacy results from the phase 1 RP-A501 study (NCT03882437) of its investigational gene therapy RP-A501, noting that the treatment was well tolerated on the whole, and that all the patients …